[go: up one dir, main page]

WO2010124222A3 - Vegf and vegfr1 gene expression useful for cancer prognosis - Google Patents

Vegf and vegfr1 gene expression useful for cancer prognosis Download PDF

Info

Publication number
WO2010124222A3
WO2010124222A3 PCT/US2010/032261 US2010032261W WO2010124222A3 WO 2010124222 A3 WO2010124222 A3 WO 2010124222A3 US 2010032261 W US2010032261 W US 2010032261W WO 2010124222 A3 WO2010124222 A3 WO 2010124222A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
gene expression
cancer prognosis
expression useful
vegfr1 gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/032261
Other languages
French (fr)
Other versions
WO2010124222A2 (en
Inventor
Heinz-Josef Lenz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Priority to US13/265,538 priority Critical patent/US20120108445A1/en
Publication of WO2010124222A2 publication Critical patent/WO2010124222A2/en
Publication of WO2010124222A3 publication Critical patent/WO2010124222A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides compositions and methods for determining the likelihood of tumor recurrence of adjuvant cancer patients following surgical resection.
PCT/US2010/032261 2009-04-24 2010-04-23 Vegf and vegfr1 gene expression useful for cancer prognosis Ceased WO2010124222A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/265,538 US20120108445A1 (en) 2009-04-24 2010-04-23 Vegf and vegfr1 gene expression useful for cancer prognosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17256209P 2009-04-24 2009-04-24
US61/172,562 2009-04-24

Publications (2)

Publication Number Publication Date
WO2010124222A2 WO2010124222A2 (en) 2010-10-28
WO2010124222A3 true WO2010124222A3 (en) 2011-03-10

Family

ID=42315886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/032261 Ceased WO2010124222A2 (en) 2009-04-24 2010-04-23 Vegf and vegfr1 gene expression useful for cancer prognosis

Country Status (2)

Country Link
US (1) US20120108445A1 (en)
WO (1) WO2010124222A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012344155A1 (en) 2011-11-28 2014-07-03 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Methods and kits for the prognosis of colorectal cancer
WO2014191559A1 (en) * 2013-05-30 2014-12-04 Institució Catalana De Recerca I Estudis Avançats Methods and kits for the prognosis of colorectal cancer
US10189881B2 (en) 2013-07-26 2019-01-29 The Regents Of The University Of California MPS peptides and use thereof
JP2019528323A (en) * 2016-08-31 2019-10-10 バイオアトラ、エルエルシー Conditionally active polypeptide and method for producing the same

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
GUSTAVSSON BENGT ET AL: "Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes", INTERNATIONAL JOURNAL OF CANCER, vol. 124, no. 5, March 2009 (2009-03-01), pages 1220 - 1226, XP002592265, ISSN: 0020-7136 *
ISHIGAMI S -I ET AL: "Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer", BRITISH JOURNAL OF CANCER, vol. 78, no. 10, November 1998 (1998-11-01), pages 1379 - 1384, XP002592264, ISSN: 0007-0920 *
KURAMOCHI H ET AL: "Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer", CLINICAL CANCER RESEARCH 20060101 US LNKD- DOI:10.1158/1078-0432.CCR-05-1275, vol. 12, no. 1, 1 January 2006 (2006-01-01), pages 29 - 33, XP002592263, ISSN: 1078-0432 *
LURJE G ET AL: "Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO OCT 2008 LNKD- PUBMED:18550579, vol. 19, no. 10, October 2008 (2008-10-01), pages 1734 - 1741, XP002592270, ISSN: 1569-8041 *
NING, Y. ET AL.: "VEGF and VEGFR1 gene expression levels and tumor recurrence in adjuvant colon cancer.", 2 June 2009 (2009-06-02), XP002592262, Retrieved from the Internet <URL:http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33183> [retrieved on 20100712] *
SCHNEIDER SYLKE ET AL: "Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation", PHARMACOGENETICS AND GENOMICS, vol. 16, no. 8, August 2006 (2006-08-01), pages 555 - 563, XP009136313, ISSN: 1744-6872 *
VALLBOHMER DANIEL ET AL: "Molecular determinants of irinotecan efficacy", INTERNATIONAL JOURNAL OF CANCER, vol. 119, no. 10, November 2006 (2006-11-01), pages 2435 - 2442, XP002592266, ISSN: 0020-7136 *
WATANABE TOSHIAKI ET AL: "Molecular predictors of survival after adjuvant chemotherapy for colon cancer", NEW ENGLAND JOURNAL OF MEDICINE, vol. 344, no. 16, 19 April 2001 (2001-04-19), pages 1196 - 1206, XP002592267, ISSN: 0028-4793 *
YANG DONGYUN ET AL: "Gene Expression Levels of Epidermal Growth Factor Receptor, Survivin, and Vascular Endothelial Growth Factor as Molecular Markers of Lymph Node Involment in Patients with Locally Advanced Rectal Cancer", CLINICAL COLORECTAL CANCER, XX, US LNKD- DOI:10.3816/CCC.2006.N.049, vol. 6, no. 4, 1 November 2006 (2006-11-01), pages 305 - 311, XP008096138, ISSN: 1533-0028 *

Also Published As

Publication number Publication date
WO2010124222A2 (en) 2010-10-28
US20120108445A1 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
WO2012103250A3 (en) Colon cancer gene expression signatures and methods of use
WO2009092108A3 (en) Biomarkers for the diagnosis and treatment of pancreatic cancer
WO2010102195A3 (en) Annexin a11 and associated genes as biomarkers for cancer
WO2010045586A3 (en) Muc-1 cytoplasmic domain peptides as inhibitors of cancer
WO2009026128A3 (en) Gene expression markers of recurrence risk in cancer patients after chemotherapy
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
WO2010099161A8 (en) Micrornas in never-smokers and related materials and methods
WO2012006447A3 (en) Gene signatures for cancer prognosis
WO2008079988A3 (en) Quinazolines for pdk1 inhibition
DK2621481T4 (en) Dual inhibitors of MET and VEGF for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
WO2014018563A3 (en) Methods for the treatment of cancer
WO2011008262A9 (en) Methods and apparatus for diagnosis and/or prognosis of cancer
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
WO2012068381A9 (en) Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
WO2012021887A3 (en) Biomarkers for the early detection of breast cancer
WO2010146059A3 (en) Biomarkers for igf-1r inhibitor therapy
WO2012170776A3 (en) Methods of determining a patient&#39;s prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
MA34057B1 (en) Formulations and methods for the diagnosis and treatment of tumor
AU2008260399A8 (en) Vaccine for the prevention of breast cancer relapse
WO2011146568A8 (en) Predicting response to a her inhibitor
WO2010091384A3 (en) Cadherin-11 inhibitors and methods of use thereof
EP2329044A4 (en) Prmt1 for target genes of cancer therapy and diagnosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10716220

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13265538

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 10716220

Country of ref document: EP

Kind code of ref document: A2